PE20130232A1 - Conjugados para la prevencion o el tratamiento de la adiccion a la nicotina - Google Patents

Conjugados para la prevencion o el tratamiento de la adiccion a la nicotina

Info

Publication number
PE20130232A1
PE20130232A1 PE2012002273A PE2012002273A PE20130232A1 PE 20130232 A1 PE20130232 A1 PE 20130232A1 PE 2012002273 A PE2012002273 A PE 2012002273A PE 2012002273 A PE2012002273 A PE 2012002273A PE 20130232 A1 PE20130232 A1 PE 20130232A1
Authority
PE
Peru
Prior art keywords
conjugates
prevention
treatment
nicotine addiction
nicotine
Prior art date
Application number
PE2012002273A
Other languages
English (en)
Inventor
Nickolas Anastasiou
Keshab Bhattacharya
Alan Daniel Brown
Heather Lynn Davis
Jari Illmari Finneman
David P Gervais
Lyn Howard Jones
Parag Ashok Kolhe
Michael John Mccluskie
Paul Robert Mehelic
James Richard Merson
Erin Kristen Parsons
David Cameron Pryde
David Robert Stead
Jennifer Marie Thorn
Original Assignee
Pfizer Vaccines Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44343221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130232(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Vaccines Llc filed Critical Pfizer Vaccines Llc
Publication of PE20130232A1 publication Critical patent/PE20130232A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

SE REFIERE A CONJUGADOS DE HAPTENO-VEHICULO DERIVADO DE NICOTINA DE FORMULA (III), DONDE: W ES CH2 U O, QUE SE ENCUENTRA EN POSICION 2, 5 O 6 DEL ANILLO PIRIDINA; (ESPACIADOR) ES ALQUILENO C1-C8, CICLOALQUILENO C3-10 O ALQUILENO C1-12 INTERRUMPIDO POR 1 A 4 ATOMOS DE O Y OPCIONALMENTE POR N(H)C(O); X* ES NH2 O S; m ES 0 O 1; n ES UN ENTERO DE 1 A 1000; Y ES UNA PROTEINA PORTADORA TAL COMO TOXOIDES, LIPOSOMAS, VIRUS, COMPLEJOS INIMUNOESTIMULADORES, SUSTANCIAS INMUNOGENICAS, ENTRE OTROS. REFERIDO ADEMAS A COMPOSICIONES DE VACUNAS QUE CONTIENEN DICHOS CONJUGADOS, SIENDO UTILES PARA EL TRATAMIENTO O PREVENCION DE LA DEPENDENCIA A LA NICOTINA
PE2012002273A 2010-06-04 2011-06-03 Conjugados para la prevencion o el tratamiento de la adiccion a la nicotina PE20130232A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35134210P 2010-06-04 2010-06-04

Publications (1)

Publication Number Publication Date
PE20130232A1 true PE20130232A1 (es) 2013-03-10

Family

ID=44343221

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002273A PE20130232A1 (es) 2010-06-04 2011-06-03 Conjugados para la prevencion o el tratamiento de la adiccion a la nicotina

Country Status (21)

Country Link
US (2) US8980276B2 (es)
EP (1) EP2575893A1 (es)
JP (2) JP5723976B2 (es)
KR (1) KR101429413B1 (es)
CN (2) CN102933237B (es)
AR (1) AR081299A1 (es)
AU (1) AU2011262221B2 (es)
BR (1) BR112012031360A2 (es)
CA (1) CA2800882C (es)
CO (1) CO6650413A2 (es)
HK (2) HK1182029A1 (es)
IL (1) IL223279A0 (es)
MX (1) MX342680B (es)
MY (1) MY158200A (es)
NZ (1) NZ603819A (es)
PE (1) PE20130232A1 (es)
RU (1) RU2574032C2 (es)
SG (1) SG186090A1 (es)
TW (2) TWI578997B (es)
WO (1) WO2011151807A1 (es)
ZA (1) ZA201300079B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
PL2376107T3 (pl) * 2008-12-09 2014-09-30 Coley Pharm Group Inc Oligonukleotydy immunostymulujące
EP2917183A1 (en) 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same
EA032441B1 (ru) * 2013-09-05 2019-05-31 Иммьюн Дизайн Корп. Вакцинные композиции против никотиновой зависимости
US9303013B2 (en) * 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
AU2015264325B2 (en) * 2014-05-19 2019-02-14 The Scripps Research Institute Enantiopure haptens for nicotine vaccine development
CN106496309A (zh) * 2016-11-24 2017-03-15 北京开景基因技术有限公司 微球抗原及其制备方法以及抗可替宁抗体的制备方法
EP3565531A4 (en) * 2017-01-05 2020-07-29 Chenming Zhang NICOTINE-BASED NANOVACCINS AND THEIR USES
WO2020176791A1 (en) * 2019-02-28 2020-09-03 Nano Vape Corporation Nitric oxide releasing vaping formulations, compounds, use, and methods of forming

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2315314A (en) * 1941-06-10 1943-03-30 Tobacco By Products And Chemic Nicotine derivative
US3964482A (en) 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
JPH02219595A (ja) * 1988-09-02 1990-09-03 Matsushita Electric Ind Co Ltd ハプテンである抗原に対し高親和性を持つ抗体
US5015741A (en) 1989-10-03 1991-05-14 Philip Morris Incorporated Nicotine analogs
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
SE9801923D0 (sv) * 1998-05-29 1998-05-29 Independent Pharmaceutical Ab Nicotine vaccine
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
SE0000933D0 (sv) * 2000-03-21 2000-03-21 Independent Pharmaceutica Ab Method of producing 6-substituted (S)-nicotine derivatives and intermediate compounds
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6494844B1 (en) 2000-06-21 2002-12-17 Sanarus Medical, Inc. Device for biopsy and treatment of breast tumors
GB0017999D0 (en) 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
WO2002064193A2 (en) 2000-12-14 2002-08-22 Georgia Tech Research Corporation Microneedle devices and production thereof
GB0031079D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Vaccine
WO2002058635A2 (en) 2001-01-26 2002-08-01 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
US6767341B2 (en) 2001-06-13 2004-07-27 Abbott Laboratories Microneedles for minimally invasive drug delivery
US6745211B2 (en) 2001-11-21 2004-06-01 Ge Financial Assurance Holdings, Inc. Method and system for verifying and correcting data records in a database
US20050089524A1 (en) 2002-03-01 2005-04-28 Sanderson Sam D. Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
AU2003277306A1 (en) 2002-10-07 2004-05-04 Biovalve Technologies, Inc. Microneedle array patch
WO2005040338A2 (en) 2003-05-21 2005-05-06 The Scripps Research Institute Constrained alkaloid immunogens and antibodies and uses thereof
US7112678B2 (en) 2003-11-17 2006-09-26 North Carolina State University Regiospecific synthesis of nicotine derivatives
CA2560840C (en) 2004-03-24 2014-05-06 Corium International, Inc. Transdermal delivery device
US20060111271A1 (en) 2004-11-24 2006-05-25 Cerny Erich H Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements
CA2612005C (en) 2005-06-17 2013-10-29 Georgia Tech Research Corporation Coated microstructures and method of manufacture thereof
EP1849780A1 (en) 2006-04-21 2007-10-31 De Staat der Nederlanden, vert. door de minister van VWS Vaccine against nicotine addiction
EP2146689B1 (en) 2007-04-16 2020-08-12 Corium, Inc. Solvent-cast microneedle arrays containing active
WO2010056922A2 (en) 2008-11-12 2010-05-20 Kythera Biopharmaceuticals, Inc. Systems and methods for delivery of biologically active agents
EP2477974A2 (en) 2009-09-14 2012-07-25 The Scripps Research Institute Nicotine haptens, immunoconjugates and their uses

Also Published As

Publication number Publication date
JP6047611B2 (ja) 2016-12-21
TW201208700A (en) 2012-03-01
SG186090A1 (en) 2013-01-30
TWI578997B (zh) 2017-04-21
BR112012031360A2 (pt) 2017-05-02
IL223279A0 (en) 2013-02-03
WO2011151807A1 (en) 2011-12-08
KR101429413B1 (ko) 2014-08-11
HK1182029A1 (en) 2013-11-22
MX342680B (es) 2016-10-07
US20150157708A1 (en) 2015-06-11
CN102933237A (zh) 2013-02-13
CN104945374A (zh) 2015-09-30
MY158200A (en) 2016-09-15
JP2015147785A (ja) 2015-08-20
MX2012014025A (es) 2013-02-12
CA2800882A1 (en) 2011-12-08
US20110300174A1 (en) 2011-12-08
US8980276B2 (en) 2015-03-17
ZA201300079B (en) 2013-09-25
AU2011262221B2 (en) 2014-07-17
RU2012153061A (ru) 2014-07-20
AR081299A1 (es) 2012-08-01
KR20130043146A (ko) 2013-04-29
TW201505652A (zh) 2015-02-16
TWI455722B (zh) 2014-10-11
JP5723976B2 (ja) 2015-05-27
HK1214250A1 (zh) 2016-07-22
RU2574032C2 (ru) 2016-01-27
EP2575893A1 (en) 2013-04-10
CO6650413A2 (es) 2013-04-15
CA2800882C (en) 2016-01-19
CN102933237B (zh) 2015-06-10
NZ603819A (en) 2014-11-28
AU2011262221A1 (en) 2012-12-13
JP2013528616A (ja) 2013-07-11

Similar Documents

Publication Publication Date Title
PE20130232A1 (es) Conjugados para la prevencion o el tratamiento de la adiccion a la nicotina
IN2012DN02736A (es)
MX341395B (es) Compuestos (lipopeptidos basados en cisteina) y composiciones como agonistas de tlr2 usados para el tratamiento de infecciones, inflamaciones, enfermedades respiratorias, etc.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA201270356A1 (ru) Иммуногенные композиции, содержащие модуляторы активности tlr
EA202090699A3 (ru) Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
EA201390538A1 (ru) Противовирусные соединения
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
PH12015500243B1 (en) Glycoconjugation processes and compositions
MA35110B1 (fr) Protéines de fusion et polyvaccins comprenant la protéine e et la piline a d'haemophilus influenzae
EA201100268A1 (ru) Вакцина
CO6690760A2 (es) Variantes no lipidadas de antígenos orf2086 de neisseria meningitidis
MX2016007865A (es) Peptidos citotoxicos y conjugados de los mismos.
GB201101665D0 (en) Immunogenic compositions
MX2015002482A (es) Composicion inmunogenica.
EA201290956A1 (ru) Вакцина против вич
CL2012000744A1 (es) Proceso para preparar un conjugado de polisacáridos capsulares tipo 5 o tipo 8 de s. aureus y una molécula transportadora; conjugado de polisacáridos; y composición inmunogénica que lo comprende.
EA201590427A1 (ru) Нелинейные сахаридные конъюгаты
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
MX2021015972A (es) Vacuna contra la fiebre aftosa.
MX2010006984A (es) Vacunas contra la malaria.
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
MX2012004922A (es) Compuesto de 5,6-dihidro-1h-piridin-2-ona deuterados.
EA201991559A1 (ru) Конъюгаты полипептид-антиген с неприродными аминокислотами
CY1114249T1 (el) Αναστολεις του ιου ηπατιτιδας c

Legal Events

Date Code Title Description
FD Application declared void or lapsed